SCHEMBL3596504

SCHEMBL3596504

CC(C)(C)OC(=O)N1CCc2cc(C(=O)Nc3cnn(Cc4ccc(Cl)c(Cl)c4)c3)ccc2C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.57
MAPT P10636 3/20 0.57
CYP1A2 P05177 2/20 0.57
CYP2C9 P11712 2/20 0.57
CYP2C19 P33261 2/20 0.57
PLA2G1B P04054 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
ATG4B Q9Y4P1 1/20 0.57
SCD O00767 2/20 0.51
SCD5 Q86SK9 1/20 0.51
NAMPT P43490 4/20 0.49
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
LMNA P02545 2/20 0.48
HPGD P15428 2/20 0.48
TP53 P04637 1/20 0.48
TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3599020 0.93 SMN1; SMN2 (0.57) SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3606619 0.91 TMPRSS2 (0.49) SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3603596 0.91 SCD (0.53) SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3615745 0.91 SCD (0.51) SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3598199 0.90 NAMPT (0.56) SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3605404 0.90 NAMPT (0.63) SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3600477 0.89 NAMPT (0.51) SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3597540 0.88 SMN1; SMN2 (0.60) SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL13844972 0.88 SCD (0.51) SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL3611560 0.88 MAPT (0.47) SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041696-A1 Compounds SMITHKLINE BEECHAM CORPORATION 2010-02-18 US claimed
US-20100041696-A1 Compounds SMITHKLINE BEECHAM CORPORATION 2010-02-18 US disclosed
US-20100041696-A1 Compounds SMITHKLINE BEECHAM CORPORATION 2010-02-18 US disclosed
US-20100041696-A1 Compounds SMITHKLINE BEECHAM CORPORATION 2010-02-18 US disclosed
WO-2008074824-A2 ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) SMITHKLINE BEECHAM CORPORATION (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041696-A1 Compounds CYP11B2, SCD, CYP3A5 SMN1; SMN2 618/4885MAPT 3377/4885CYP1A2 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.